牛牛AI助手已提取核心信息
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended report (Form 8-K/A) with the Securities and Exchange Commission (SEC) on January 9, 2024. The amendment provides updates on costs associated with the company's exit activities from a portion of its Foster City campus. Initially reported on June 26, 2023, and subsequently amended on November 13, 2023, the company has now estimated impairment charges of approximately $43 million for the fourth fiscal quarter of 2023. These charges are related to right-of-use asset and leasehold improvement impairments. Illumina continues to evaluate options for the remaining parts of its Foster City campus and may incur additional charges, the extent of which cannot be currently estimated. The company has stated that these charges will be excluded from its non-GAAP financial metrics and will file further amendments if the costs are material and estimable. The report also includes forward-looking statements with the usual caveats regarding the risks and uncertainties associated with such predictions.
Illumina, Inc., a biotechnology company based in San Diego, California, has filed an amended report (Form 8-K/A) with the Securities and Exchange Commission (SEC) on January 9, 2024. The amendment provides updates on costs associated with the company's exit activities from a portion of its Foster City campus. Initially reported on June 26, 2023, and subsequently amended on November 13, 2023, the company has now estimated impairment charges of approximately $43 million for the fourth fiscal quarter of 2023. These charges are related to right-of-use asset and leasehold improvement impairments. Illumina continues to evaluate options for the remaining parts of its Foster City campus and may incur additional charges, the extent of which cannot be currently estimated. The company has stated that these charges will be excluded from its non-GAAP financial metrics and will file further amendments if the costs are material and estimable. The report also includes forward-looking statements with the usual caveats regarding the risks and uncertainties associated with such predictions.
总部位于加利福尼亚州圣地亚哥的生物技术公司Illumina, Inc. 已于2024年1月9日向美国证券交易委员会 (SEC) 提交了修订报告（表格8-K/A）。该修正案提供了与该公司从福斯特城部分园区退出活动相关的费用的最新情况。该公司最初于2023年6月26日报告，随后于2023年11月13日进行了修订，现在估计2023年第四财季的减值费用约为4,300万美元。这些费用与使用权资产和租赁权益改善减值有关。Illumina继续评估其福斯特城校区其余部分的备选方案，可能会产生额外费用，其范围目前无法估计。该公司表示，这些费用将不包括在其非公认会计准则财务指标中，如果成本是重大且可估算的，则将提出进一步的修正。该报告还包括前瞻性陈述，并附有与此类预测相关的风险和不确定性的常见注意事项。
总部位于加利福尼亚州圣地亚哥的生物技术公司Illumina, Inc. 已于2024年1月9日向美国证券交易委员会 (SEC) 提交了修订报告（表格8-K/A）。该修正案提供了与该公司从福斯特城部分园区退出活动相关的费用的最新情况。该公司最初于2023年6月26日报告，随后于2023年11月13日进行了修订，现在估计2023年第四财季的减值费用约为4,300万美元。这些费用与使用权资产和租赁权益改善减值有关。Illumina继续评估其福斯特城校区其余部分的备选方案，可能会产生额外费用，其范围目前无法估计。该公司表示，这些费用将不包括在其非公认会计准则财务指标中，如果成本是重大且可估算的，则将提出进一步的修正。该报告还包括前瞻性陈述，并附有与此类预测相关的风险和不确定性的常见注意事项。
有用
没用